Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARDNASDAQ:AVTENASDAQ:GNFTNASDAQ:MDCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$11.76+0.9%$9.29$4.88▼$19.58$255.15MN/A103,935 shs24,427 shsAVTEAerovate Therapeutics$7.25+0.7%$48.19$43.75▼$884.98$210.14M0.9518,910 shs390,996 shsGNFTGenfit$4.61+2.2%$3.86$2.55▼$6.42$230.48M0.9213,371 shs481 shsMDCXMedicus Pharma$2.84+12.3%$4.48$1.80▼$8.94$38.55MN/A126,399 shs256,192 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics+4.76%+18.74%-9.33%+2.46%+1,165,999,900.00%AVTEAerovate Therapeutics-0.69%+2.42%-42.31%-91.67%-98.82%GNFTGenfit+3.99%+5.28%+5.37%+27.58%-19.46%MDCXMedicus Pharma-3.80%-58.93%-42.63%-17.59%+252,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAARDAardvark TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAVTEAerovate Therapeutics1.9802 of 5 stars3.00.00.00.03.21.70.6GNFTGenfit2.4642 of 5 stars3.55.00.00.03.00.00.0MDCXMedicus Pharma1.9334 of 5 stars3.80.00.00.02.90.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 3.00Buy$31.25168.01% UpsideAVTEAerovate Therapeutics 2.00Hold$78.75993.75% UpsideGNFTGenfit 3.00Buy$13.00190.18% UpsideMDCXMedicus Pharma 3.50Strong Buy$23.50843.78% UpsideCurrent Analyst Ratings BreakdownLatest MDCX, AARD, GNFT, and AVTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.005/22/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.005/15/2025AARDAardvark TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.005/12/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $27.005/8/2025MDCXMedicus PharmaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $20.004/28/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/21/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/14/2025MDCXMedicus PharmaD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/14/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.004/1/2025AARDAardvark TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$21.00 ➝ $21.004/1/2025AARDAardvark TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$50.00 ➝ $50.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/AN/AN/AAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/AGNFTGenfit$67.00M3.34N/AN/A$1.48 per share3.03MDCXMedicus PharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/AAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%8/11/2025 (Estimated)GNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/A7/24/2025 (Estimated)MDCXMedicus PharmaN/AN/A0.00N/AN/AN/AN/AN/A6/27/2025 (Estimated)Latest MDCX, AARD, GNFT, and AVTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025N/AAARDAardvark Therapeutics-$0.70-$0.71-$0.01-$0.71N/AN/A5/12/2025Q1 2025MDCXMedicus Pharma-$0.23-$0.42-$0.19-$0.42N/AN/A4/25/2025Q4 2024AVTEAerovate Therapeutics-$10.50-$3.15+$7.35-$0.09N/AN/A3/28/2025Q4 2024MDCXMedicus Pharma-$0.32-$0.18+$0.14-$0.18N/AN/A3/27/2025Q4 2024AVTEAerovate Therapeutics-$6.65-$6.65N/A-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/AAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/ALatest MDCX, AARD, GNFT, and AVTE DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/9/2025AVTEAerovate Therapeutics$84.004/29/20254/25/20254/28/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/AN/AN/AAVTEAerovate TherapeuticsN/A8.788.78GNFTGenfit0.613.743.74MDCXMedicus PharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/AAVTEAerovate TherapeuticsN/AGNFTGenfit2.24%MDCXMedicus PharmaN/AInsider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/AAVTEAerovate Therapeutics24.90%GNFTGenfit4.20%MDCXMedicus PharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.70 millionN/AN/AAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableGNFTGenfit12050.00 million47.90 millionNot OptionableMDCXMedicus PharmaN/A13.57 millionN/AN/AMDCX, AARD, GNFT, and AVTE HeadlinesRecent News About These CompaniesMedicus Pharma completes $7 million public offeringJune 4 at 3:42 AM | uk.investing.comMedicus Pharma Ltd. Announces Closing of $7.0 Million Public OfferingJune 2 at 1:40 PM | newsfilecorp.comMedicus Pharma (NASDAQ:MDCX) Upgraded to "Hold" at Wall Street ZenMay 31, 2025 | americanbankingnews.comMedicus Pharma (NASDAQ:MDCX) Upgraded at Wall Street ZenMay 31, 2025 | marketbeat.comMedicus Pharma (NASDAQ:MDCX) Earns Buy Rating from D. Boral CapitalMay 31, 2025 | americanbankingnews.comD. Boral Capital Reiterates "Buy" Rating for Medicus Pharma (NASDAQ:MDCX)May 30, 2025 | marketbeat.comMedicus Pharma unveils pricing of $7M public offeringMay 30, 2025 | proactiveinvestors.comMedicus Pharma prices $7 million share offeringMay 30, 2025 | msn.comMedicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering | MDCX Stock NewsMay 29, 2025 | gurufocus.comMedicus Pharma Ltd. Launches $7 Million Public Offering to Advance Cancer Treatment TrialsMay 29, 2025 | tipranks.comMedicus Pharma Ltd. Announces Pricing of $7.0 Million Public OfferingMay 29, 2025 | newsfilecorp.comMDCX Medicus Pharma Ltd.May 29, 2025 | seekingalpha.comMedicus Pharma begins UAE cancer trial expansion – ICYMIMay 25, 2025 | proactiveinvestors.comMedicus Pharma begins UAE cancer trial expansion – ICYMIMay 25, 2025 | proactiveinvestors.comMedicus Pharma's (MDCX) Buy Rating Reaffirmed at D. Boral CapitalMay 24, 2025 | marketbeat.comMedicus Pharma gets UAE approval for Phase 2 study for skin cancer therapyMay 22, 2025 | proactiveinvestors.comMedicus Pharma gets UAE approval for Phase 2 study for skin cancer therapyMay 22, 2025 | proactiveinvestors.comMedicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)May 22, 2025 | newsfilecorp.comMedicus Pharma Ltd. (NASDAQ:MDCX) Major Shareholder Velocity Fund Partners, Lp Sells 75,000 SharesMay 22, 2025 | insidertrades.comMedicus Pharma (NASDAQ:MDCX) Announces Earnings Results, Misses Estimates By $0.19 EPSMay 14, 2025 | marketbeat.comD. Boral Capital Boosts Medicus Pharma (NASDAQ:MDCX) Price Target to $27.00May 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDCX, AARD, GNFT, and AVTE Company DescriptionsAardvark Therapeutics NASDAQ:AARD$11.76 +0.10 (+0.86%) As of 01:27 PM EasternAardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.Aerovate Therapeutics NASDAQ:AVTE$7.25 +0.05 (+0.69%) As of 06/3/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Genfit NASDAQ:GNFT$4.61 +0.10 (+2.22%) As of 12:22 PM EasternGenfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Medicus Pharma NASDAQ:MDCX$2.84 +0.31 (+12.25%) As of 01:28 PM EasternMedicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Guidewire Rockets Higher: A Move Above $300 Is Probable TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Analog Devices' Cyclical Recovery Story Has Just Begun Microsoft Stock Near Peak, Pullback Seen as Opportunity 3 Reasons Amazon Could Be the Best Tech Performer in June 3 Tech Stocks Insiders Are Buying: Speculative Plays for June Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
